ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0214

The Structured Curriculum Development Significantly Increased the Pediatric Residents’ Competency and Confidence During a 4-week Pediatric Rheumatology Rotation
Abstract Number: 0613

The Subsets of Synovial Fluid Derived Fibroblasts in Clinical Features of Rheumatoid Arthritis
Abstract Number: 2071

The Systemic Lupus Erythematosus International Collaborating Clinics (SLICC), American College of Rheumatology (ACR), and Lupus Foundation of America (LFA) Damage Index Revision – Item Generation Phase
Abstract Number: 1579

The TICOG Study: Tight Control of Gout – A Randomized, Controlled Trial of Targeted versus Conventional Treatment for Gout Including Ultrasonography
Abstract Number: 1665

The TLR7/8 Inhibitor Enpatoran Reverses Established Kidney Disease in the Interferon-Alpha-Accelerated NZB/W Mouse Model of Lupus
Abstract Number: 1186

The Trajectory of Multimorbidity in Patients with Systemic Lupus Erythematosus in the United States
Abstract Number: 1716

The Transcriptomic Landscape of Nephritic Kidneys Reveals Mechanisms for End Organ Resistance to Damage in Lupus-prone Mice
Abstract Number: 2039

The Tubarial Glands Resemble the Palatal Salivary Glands Based on Further Histological Characterization, and May Represent an Organ of Interest in Primary Sjögren’s Syndrome
Abstract Number: 1827

The Updated Cardiovascular Risk Tool SCORE2 Provides No Advantage in Identifying Patients with Gout and Carotid Atheroma Plaques
Abstract Number: 0771

The Use of a bDMARD or tsDMARD for the Management of Rheumatic irAE Under Checkpoint Inhibitors: An Observational Study
Abstract Number: 0961

The Use of Belimumab Before and During Pregnancy in Patients with Systemic Lupus Erythematosus: An Italian Multicenter Case-series
Abstract Number: 2104

The Use of Cell-bound Complement Activation Product to Assess Disease Activity in SLE
Abstract Number: 0278

The Use of Exposure-Adjusted Event Rates versus Exposure-Adjusted Incidence Rates in Adverse Event Reporting: Insights from Filgotinib Integrated Safety Data in RA
Abstract Number: 0459

The Use of Intravenous Methylprednisolone in Patients with Giant Cell Arteritis: A Population-Based Study
Abstract Number: PP14

The Use of Social Support as Treatment

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].